The BCL-2 arbiters of apoptosis and their growing role as cancer targets

Cell Death and Differentiation
Jerry M Adams, Suzanne Cory

Abstract

Impaired apoptosis plays a central role in cancer development and limits the efficacy of conventional cytotoxic therapies. Deepening understanding of how opposing factions of the BCL-2 protein family switch on apoptosis and of their structures has driven development of a new class of cancer drugs that targets various pro-survival members by mimicking their natural inhibitors, the BH3-only proteins. These 'BH3 mimetic' drugs seem destined to become powerful new weapons in the arsenal against cancer. Successful clinical trials of venetoclax/ABT-199, a specific inhibitor of BCL-2, have led to its approval for a refractory form of chronic lymphocytic leukaemia and to scores of on-going trials for other malignancies. Furthermore, encouraging preclinical studies of BH3 mimetics that target other BCL-2 pro-survival members, particularly MCL-1, offer promise for cancers resistant to venetoclax. This review sketches the impact of the BCL-2 family on cancer development and therapy, describes how interactions of family members trigger apoptosis and discusses the potential of BH3 mimetic drugs to advance cancer therapy.

References

Apr 3, 1992·Cell·G I EvanD C Hancock
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·A StrasserA W Harris
Oct 15, 1998·Proceedings of the National Academy of Sciences of the United States of America·C G PrintS Cory
Jul 26, 2003·Science·Emily H Y ChengStanley J Korsmeyer
Dec 12, 2003·Nature·Joseph T OpfermanStanley J Korsmeyer
Apr 14, 2004·Proceedings of the National Academy of Sciences of the United States of America·Alexander EgleSuzanne Cory
May 20, 2005·Nature·Tilman OltersdorfSaul H Rosenberg
May 28, 2005·The EMBO Journal·Matthew G AnnisDavid W Andrews
Jan 4, 2007·The Journal of Clinical Investigation·Victoria Del Gaizo MooreAnthony Letai
Mar 27, 2007·Cell·Kylie D MasonBenjamin T Kile
May 3, 2008·Cancer Research·Christin TseSteven W Elmore
Jun 14, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Nicole ArbourRuth S Slack
Jun 25, 2008·Molecular and Cellular Biology·Sean P GarrisonGerard P Zambetti
Oct 25, 2008·Nature·Evripidis GavathiotisLoren D Walensky
Nov 14, 2008·Proceedings of the National Academy of Sciences of the United States of America·Kylie D MasonAndrew W Roberts
Dec 2, 2008·Nature Reviews. Drug Discovery·Guillaume LessenePeter M Colman
Jan 8, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Binje VickHenning Schulze-Bergkamen
Dec 17, 2009·The Journal of Biological Chemistry·Stephanie BleickenEnrica Bordignon
Feb 19, 2010·Nature·Rameen BeroukhimMatthew Meyerson
Jun 24, 2010·Blood·Jose A Richter-LarreaJose A Martinez-Climent
Nov 13, 2010·Molecular Cell·Evripidis GavathiotisLoren D Walensky

❮ Previous
Next ❯

Citations

Jul 13, 2018·Veterinary and Comparative Oncology·K PatatsosC J Hawkins
Nov 6, 2018·Nature Reviews. Drug Discovery·Michael P Murphy, Richard C Hartley
Oct 12, 2018·Proceedings of the National Academy of Sciences of the United States of America·Joseph M RogersHiroaki Suga
Oct 17, 2018·Acta Obstetricia Et Gynecologica Scandinavica·Sakthivignesh Ponandai-SrinivasanAngelique Floter Radestad
Mar 21, 2019·Journal of Molecular Cell Biology·Sofi E ErikssonKlas G Wiman
Apr 11, 2019·Expert Opinion on Drug Metabolism & Toxicology·Anna Korycka-WolowiecTadeusz Robak
Jun 11, 2019·Expert Opinion on Drug Discovery·Thomas FischerRainer Riedl
Oct 21, 2018·Genes and Immunity·Giuseppe RaschellàAlessandra Gambacurta
Aug 8, 2018·Molecular Systems Biology·Benjamin D LandryMichael J Lee
Aug 17, 2019·Cell Cycle·Caterina LannaLuca Bianchi
Sep 8, 2019·Cellular and Molecular Life Sciences : CMLS·Fangfang YangTongsheng Chen
Sep 5, 2019·Cells·João M A DelouHelena L Borges
Nov 16, 2019·Cell Research·Jerry M Adams
Aug 24, 2019·Molecular Oncology·Gerry MelinoFrancesca Bernassola
Jul 13, 2019·Cell Death and Differentiation·Paul M NguyenTracy L Putoczki
Dec 14, 2019·Current Opinion in HIV and AIDS·Matthew A Szaniawski, Adam M Spivak
Aug 23, 2019·Cell Death and Differentiation·Flavie StrappazzonFrancesco Cecconi
Apr 7, 2020·International Journal of Cancer. Journal International Du Cancer·Hsin-Yi TsengStuart Gallagher
Feb 1, 2020·Pharmaceutical Nanotechnology·Arjun SharmaRashmi K Ambasta
Aug 14, 2020·Journal of Cellular and Molecular Medicine·Jessica PetitiDaniela Cilloni
Aug 20, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Murat KabaklıoğluRecep Eröz
Sep 10, 2020·Apoptosis : an International Journal on Programmed Cell Death·Sehime Gulsun TemelOzgur Kutuk

❮ Previous
Next ❯

Methods Mentioned

BETA
atomic force microscopy
NMR
xenografts
xenograft
transgenic

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.